Membrane endothelial protein C receptor expression in renal tissue of pediatric lupus nephritis patients by Fattah Ibrahim, Magid A. et al.
Egypt J Pediatr Allergy Immunol 2019;17(1):37-44. 
37 
 




The general consensus is that 60% of systemic 
lupus erythematosus (SLE) patients will develop 
nephritis at some time in the course of their 
illness1,2, with a reported 5–22% of these patients 
progressing to end-stage renal disease requiring 
dialysis or transplantation3.   
Lupus nephritis (LN) is usually initially 
asymptomatic, although a few children develop 
gross hematuria or edema associated with nephrotic 
syndrome4. Nephritis is thought to be caused by 
local deposition of autoantibodies and immune 
complexes, but there is an increasing agreement 
that infiltrating leukocytes also contribute to kidney 
damage. Histological studies have demonstrated a 
correlation between the extent of this infiltration, 
impaired renal functions and an unfavorable 
prognosis5. 
EPCR is a prominent inducer of anti-apoptotic 
pathways in endothelial cells, and thus maintains 
vascular tone and normal blood flow in the 
microvasculature6. Protein C (PC) binds to EPCR 
which is expressed by endothelial cells and thus it 
has as a potent anticoagulant mechanism and potent 
anti-inflammatory properties7.  
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Background: Lupus nephritis (LN) is more common and more severe is 
pediatric systemic lupus erythematosus (pSLE).  Endothelial protein C 
receptor (EPCR) is an inducer of anti-apoptotic pathways in endothelial 
cells.  Recent studies have taken elevated anti-injury biomarkers as EPCR 
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evaluate the membrane expression of endothelial protein C receptor 
(mEPCR) in the renal microvasculature in pediatric patients with LN. 
Methods This study was conducted on 25 patients with pSLE following up at 
the Allergy and Immunology Clinic, Children’s Hospital, Ain Shams 
University. The 25 patients have LN proved by a previous renal biopsy. 
Medical history, clinical examination and routine laboratory investigations 
for assessment of disease activity were done for all patients.  Paraffin blocks 
of patients’ renal biopsies were subjected to immunohistochemistry staining 
for the frequency of mEPCR. Results: mEPCR was mainly expressed in the 
endothelium of the peritubular capillaries. Our results showed that an equal 
number of patients had nil and mild marker expression (8 patients each, 
32%) while 9 patients (36%) showed moderate/strong marker expression. 
We found that 9 out of 10 (90%) of patients with class II  had nil/mild 
marker expression, 5 patients out of 9 (55.5%)  with class III had 
mild/moderate marker expression, while 5 patients 0ut of 6 (83.3%) with 
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significant statistical difference between the different degrees of mEPCR 
expression regarding 24 hours urinary proteins. No statistical significance 
was found between the different degrees of mEPCR expression and different 
immuno-suppressive therapy dose/kg or renal outcome using the renal 
British Isles Lupus Assessment Group (BILAG) score; in spite that most of 
the patients who got improved had nil/mild marker expression. Conclusion: 
 mEPCR -bearing a statistically significant difference in relation to different 
LN classes- showed more expression in the more aggressive classes; a 
finding which might suggest a contribution of the endothelium of the renal 
parenchyma to the pathophysiology of more progressive LN. Hence the 
tissue marker might emerge as a potential new therapeutic target in the 
search for more selective treatment for SLE. 
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Recent studies have taken elevated anti-injury 
biomarkers (mEPCR) into consideration regarding 
their roles to antagonize LN. In vasculopathy as a 
comorbidity to LN, the persistent expression of 
mEPCR at peritubular capillaries may represent a 
response to the local cues of a deficit of active 
protein C8.  
Under conditions of unresolved morbidity, 
mEPCR may represent a physiologic attempt to 
limit further endothelial damage, and the observed 
increase in plaque and progression of LN represent 
an overwhelming of this reparative process by 
disease- provoking stimuli8. Given the prediction 
that shed mEPCR impairs the integrity of the 
endothelium and places the net balance of this 
protective protein in biological ‘arrears’, a decrease 
in mEPCR expression was the predicted result in 
patients with progressive renal injury9.   However, it 
was found that mEPCR is highly expressed in the 
cortical peritubular capillaries of kidneys from 
patients with active LN. This profound up 
regulation of mEPCR was observed even in areas 
with absent tubulointerstitial damage; it was 
therefore hypothesized that mEPCR may be an 
important anti-injury molecule in the cascade(s) 
leading to renal damage in SLE9. 
 
OBJECTIVES 
Evaluation of the membrane expression of 
endothelial protein C receptor (mEPCR) in the renal 
microvasculature in pediatric patients with LN and 
correlating this to SLE disease activity and 
prognosis. 
   
METHODS 
The study was an exploratory cross-sectional case 
control study conducted on 25 patients with LN 
following up at the Allergy and Immunology clinic 
in Children’s Hospital, Ain Shams University. All 
patients fulfilled at least four of the revised 
classification criteria of The American College of 
Rheumatology (ACR) for diagnosis of SLE10 and 
fulfilled the revised classification criteria of LN of 
the World Health Organization (WHO)11, for which 
they have undergone a previous renal biopsy prior 
to the study as a routine practical work up. A 
consent was obtained from each patient or their 
legal guardians before enrollment in the study. This 
study was approved by the local ethical committee 
of Ain Shams University. Paraffin blocks of renal 
biopsies of the studied patients were available at the 
archives of The Pathology department of Ain 
Shams Specialized Hospital. 
   
 
Inclusion criteria: 
• Patients with SLE disease onset before 18 years. 
Exclusion criteria: 
• Patients with any hepatic disease. 
• Patients suffering from synovitis. 
• Patients with diabetes mellitus. 
All included patients were subjected to the 
following: 
1- Detailed medical history with special emphasis 
on: 
• Demographic data: name, age, sex, and 
consanguinity. 
• Family history of similar condition. 
• Disease onset and duration. 
• History of initial renal manifestations as oliguria, 
hypertension, hematuria and edema. 
• History of complications as avascular necrosis of 
head of femur, cardiac dysfunction and renal 
performance of peritoneal and hemodialysis. 
• Clinical assessment of global disease activity 
using Systemic Lupus Erythematosus Disease 
Activity Index (SLEDAI)12 and detailed 
assessment of renal involvement using British 
Isles Lupus Assessment Group (BILAG)-2004 
renal score13 were done and Systemic Lupus 
Collaborating Clinics/American College of 
Rheumatology (SLICC/ACR) Damage Index 
(SDI) was used to assess SLE related damage14,15.   
• Activity categories have been defined on the basis 
of SLEDAI score: 
▪ No activity: 0 
▪ Mild activity: 1-5 
▪ Moderate  Activity: 6-10 
▪ High activity: 11-19 
▪ Very high activity: >20  
2- Thorough clinical examination laying stress on: 
• Assessment of anthropometric measurements 
including weight, height, and body mass index 
with calculation of standard deviation score 
(SDS)16.  
• Complete examination including cardiac, chest, 
abdominal, and neurological examination to 
assess any organ involvement and detect the 
evidence of any complication related to the 
disease or treatment. 
3- Laboratory investigations: 
• Complete blood count (CBC) using coulter 
counter (Coulter MAXMUG- HL -CCI) and 
Leishman-stained peripheral blood film 
examination for differential white blood cell 
counting. 
• Erythrocyte sedimentation rate (ESR) by 
Westergren Method. 
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• C-reactive protein (CRP) using Latex 
agglutination test (SPINREACT, S.A.Ctra. 
SPAIN). 
• Serum anti-nuclear antibody (ANA) by indirect 
immunofluorescence technique on HEP-2 cells. 
• Anti-double stranded deoxyribonucleic acid (Anti-
ds DNA) by indirect immunofluorescent 
microscopy (IMMCO Diagnostics, USA). 
• Complement-3 (C3) was estimated initially by 
nephelometry and in follow up by turbidimetry 
(Turbiquant C3, Behring Werke Diagnostics, 
Marburg, Germany). 
• Serum creatinine and serum urea levels were 
carried out on Synchron CX7 autoanalyzer 
(Beckman Instruments, Bera, California, USA). 
• Complete urine analysis. A freshly collected 
random urine specimen was collected in sterile 
plastic container and was submitted for chemical 
analysis using dipsticks and microscopic 
examination with special emphasis on the 
presence of albuminuria, hematuria, pyuria, 
urinary casts. Urine culture and sensitivity was 
done in cases with pyuria to exclude urinary tract 
infection. 
• Creatinine clearance measurement. Twenty-four 
hours urine was used to measure urinary 
creatinine, which was done using Synchron CX7 
autoanalyzer (Beckman Instruments, Bera, 
California, USA). Creatinine clearance was then 
calculated using the results of urinary and serum 
creatinine levels. 
• Twenty-four hours urinary protein measurement 
using Synchron CX7 autoanalyzer (Beckman 
Instruments, Bera, California, USA). 
4- Immunohistochemistry studies in renal biopsy: 
Twenty-five Paraffin blocks of patients with LN 
were subjected to: 
• Hematoxylin & eosin to confirm the diagnosis. 
• Immunohistochemistry staining for the frequency 
of membrane endothelial protein C receptor 
(mEPCR). 
The extent of positive staining of mEPCR was 
examined in glomerular cells (glom. mEPCR) and 
interstitial (int. mEPCR) and extent of mEPCR 
staining was graded using a scale of 0-3, where 
0=no staining (-ve), 1=mild staining (+ve), 
2=moderate staining (+ve), 3=strong staining 
(+ve)6. 
Statistical methods: 
The collected data was revised, coded, tabulated 
and introduced to a PC using Statistical package for 
Social Science (SPSS 15.0.1 for windows; SPSS 
Inc, Chicago, IL, 2001). Data was presented and 
suitable analysis was done according to the type of 
data obtained for each parameter. 
  
RESULTS 
The study included 25 patients whose age ranged 
from 5 to 18 years with a mean ± SD of 13.44 ± 
2.78. They were 3 (12%) male patients and 22 
(88%) female patients with female to male ratio 
7.3:1. Among our patients: 10 (40%) had class II 
LN, 9 (36%) patients had class III LN, 3 (12%) 
patients had class IV LN and 3 (12%) patients had 
class V LN. Accordingly, they were then classified 
to 12 (48%) having Proliferative LN (Class III and 
IV) and 11 (44%) non-proliferative LN (Class II)17. 
Hypertension was diagnosed according to the 
percentiles of blood pressure (18) and it showed that 
at presentation 6 (24%) patients had hypertension 
and on follow up only 3 (12%) had hypertension 
(on treatment). 
The age of presentation ranged from 4 and 15 
years with a mean ± SD of 11.02 ± 2.71. Duration 
of illness ranged from 1 to 5 years with a mean ± 
SD of 2.54 ± 1.63. Only 3 patients (12%) had a 
relative family history of rheumatological diseases. 
Initial renal affection evaluation done for the 
patients showed that 21 (84%) patients had 
proteinuria, 6 (24%) patients were hypertensive and 
16 (64%) patients had hematuria. In the follow up 4 
(16%) patients only were hypertensive, 3 (12%) 
patient still had hematuria and 4 (16%) patients had 
proteinuria . 
Initial anti-DNA was positive in 21 (84%) 
patients and negative in 4 (16%) patients. In the last 
follow up 10 (40%) patients had positive anti-DNA 
and 15 (60%) were negative. 
SLEDAI done at initial presentation showed that 
4 (16%) patients showed moderate activity, 12 
(48%) patients showed severe activity while 9 
(36%) patients showed very severe activity. 
Whereas, the follow up SLEDAI showed 9 (36%) 
patients had no activity, while 16 (64%) patients 
had mild disease activity, none (0%) had moderate, 
severe or very severe activity. 
The results of initial BILAG assessment for 
renal affection, showed that 7 (28%) got score A, 
8(32%) patients got score B, 6 (24%) patients got 
score C and 4 (16%) patients got score D. The 
follow up BILAG assessment showed that 2 (8%) 
got score A, 5 (20%) patients got score B, 7 (28%) 
patients got score C and 6 (24%) patients got score 
D, 5 (20%) patients got score E. The outcome of 
patients as regards renal affection was divided into 
stationary, improved and worsened. 15 (60%) 
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patients got improved, 10 (40%) were stationary 
and none (0%) worsened. 
All 25 (100%) patients were on steroids therapy 
at a dose of (0.5-2 mg/kg/day) with a cumulative 
dose that ranged between 6.4 gm and 63.33 gm with 
a median of 20 gm. 15 (60%) patients were on 
cyclophosphamide at a dose of (500-750 
mg/m2/month) with a cumulative dose ranging 
between 2.5 gm and 14.15 gm and a median of 4.1 
grams. Eight (32%) patients were on azathioprine at 
a dose of (1.5-3mg/kg/day) with a cumulative dose 
that ranged between 4.5 gm and 178 gm and a 
median of 44.7 gm. Mycophenolate Mofetil was 
given to 5 (20%) patients at a dose of (600 
mg/m2/day) maximum 2 gm with a cumulative dose 
that ranged between 150 gm and 1810 gm with a 
median of 213.9 gm. Six (24%) patients took baby 
Aspirin at the antithrombotic dose that ranged from 
(3-5mg/kg/day). 
As regards the histological findings in the renal 
tissue of the studied patients, all patients had no 
thrombotic angiopathy. The median of Activity 
index was 4.5 with a range of (2- 15), while the 
median of chronicity index was 2 with a range of 
(0-9). The rest of the histological data are 
demonstrated in table 1. Figure 1 (A, B, C) 
demonstrates the expression of mEPCR in the renal 
biopsies of patients. An equal number of patients 
had nil and mild marker expression (8 patients each, 
32%) while 9 patients (36%) showed 
moderate/strong marker expression. In a trial to 
examine the renal expression of mEPCR in relation 
to LN classes, we found that 9 out of 10 (90%) 
patients with class II had nil/mild marker 
expression, 5 out of 9 patients (55.5%) with class 
III had mild/moderate marker expression, while 5 
out of 6 patients (83.3%) with class IV and V had 
moderate/strong marker expression. A finding 
which bore a significant difference (P=0.01). 
Table 2 represents a comparison between groups 
with different degrees of mEPCR expression 
regarding some clinical and laboratory variables, 
table 3, 4 compare proliferative and non-
proliferative LN regarding histological variants, 




Figure 1. Renal expression of mEPCR using 
Immunohistological staining. 
A: Strong Immunostaining of the endothelium of peritubular 
capillaries with mEPCR 
B: Moderate expression of mEPCR in the endothelium of 
peritubular capillaries 
C: Mild expression of mEPCR in the endothelium of peritubular 




















Nil Mild Moderate Strong 
Fibrinoid necrosis 22 (88%) 2 (8%) 1 (4%) - 
Glomerular Neutrophils 13 (52%) 9 (36%) 3 (12%) - 
Endocapillary proliferation 13 (52%) 8 (32%) 2 (8%) 2 (8%) 
Crescent Formation 22 (88%) 2 (8%) 1 (4%) - 
 
Table 2. Comparison between groups with different degrees of mEPCR expression as regards some clinical 
and laboratory variables. 
 
Variable mEPCR  
P Nil/Mild Moderate/Strong 
BILAG Improved (n=15) n(%) 10 (66.6%) 5 (33.3%) 
0.73 
Stationary (n=10) n(%) 6 (60%) 4 (40%) 
BILAG score 
(at the time of renal 
biopsy) 
A (n=7) n(%) 3 (37.5%) 4 (57.1%) 
0.597 
B (n=8) n(%) 5 (62.5%) 3 (37.5%) 
C (n=6) n(%) 5 (83.3%) 1 (16.7%) 
D (n=4) n(%) 3 (75%) 1 (25%) 
Drugs Steroid (gm/kg)  
Median (range) 
0.45 (0.05- 0.71) 
(n=16) 
0.46 (0.26- 3.1) 
(n=9) 
0.45 
Cyclophosphamide (gm/kg)  
Median (range) 





Indices Activity Median (range) 5 (2-15) 4 (2-10) 0.69 
Chronicity Median (range) 1 (0-2) 3 (0-3) 0.01 
Lab. Data Lymphocytic count (×103 /µl ) 1.5 (0.6-4.3) 1.6 (0.6-4.37) 0.535 
s. creatinine (mg/dl) 0.7 (0.3-6.4) 0.6 (0.3-5.3) 0.252 
24 hrs urinary protein (gm) 0.5 (0.1-3.4) 1.4 (0.28-4) 0.049 
P <0.05: significant 
 
 










Median Range Median Range 
Activity Index 6 2-15 3 2-5 0.004 




Table 4. Comparison between proliferative and non-proliferative LN as regards histological variants. 
 
Variables 
Patients with  
Proliferative LN  
n= 12 
Patients with  
non-proliferative LN  
n=10 
P 
Nil Mild Moderate Strong Nil Mild Moderate Strong 
Fibrinoid necrosis 10 (83.3%) 1 (8.3%) 1 (8.3%) - 9 (90%) 1(10%) 0(0%) - 0.53 
Glomerular Neutrophils 3 (25%) 6(50%) 3 (25%) - 7(70%) 3 (30%) 0(0%) - 0.014 
Endocapillary 
proliferation 
1 (8.3%) 7(58.3%) 2 (16.7%) 2 (16.7%) 9(90%) 1 (10%) 0(0%) 0(0%) 0.00 
Crescent Formation 
9 (75%) 2 (16.7%) 1 (8.3%) - 
10 
(100%) 
0(0%) 0(0%) - 0.13 
Renal mEPCR 3 (25%) 4 (33.3%) 3 (25%) 2 (16.7%) 5(50%) 4(40%) 0(0%) 2(20%) 0.42 
P<0.05:significant 
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DISCUSSION 
LN has been described as the most serious 
complication of SLE and the strongest predictor of 
poor outcome19. It affects up to 80% of the patients 
with SLE20. There has been growing evidence 
suggesting that infiltration of T lymphocytes and 
other leucocytes at sites of inflammation plays a 
critical role in organ involvement in SLE21. In 
addition, cytokines were found to participate in the 
local inflammatory process that mediates tissue 
insult in SLE22,23. 
The contribution of the vascular endothelium to 
the pathogenesis of renal injury has not been 
emphasized in LN. The state of microvasculature 
has never been identified in the definition of the 
WHO classification, National Institutes of Health 
chronicity and activity indices, nor in recent 
International Society of Nephrology/Renal 
Pathology Society (ISN/RPS) 2003 pathological 
classifications of LN. Recent murine data based on 
microarray analysis suggests that endothelial 
activation is a feature observed in progressive 
glomerulosclerosis but not in non-progressive 
glomerulosclerosis6.  
The Endothelial Protein C Receptor (EPCR) is 
expressed on leukocytes, on endothelium of large 
blood vessels and to a less extent on capillaries. 
Membrane bound EPCR plays an important role in 
the activation of protein C that has anticoagulant, 
anti-inflammatory and cytoprotective effects24. 
Accordingly, we examined the site and distribution 
of mEPCR expression in our patients’ renal 
biopsies. The main site of expression was in the 
endothelium of the peritubular capillaries. Such 
finding was confirmed by Izmirly and colleagues 
(2009) who conducted a study on 49 patients with 
LN and controls and reported that positive staining 
for mEPCR was in the peritubular capillaries in 
areas with tubulointerstitial damage, while most of 
the glomeruli were negative6. 
Given the assumption that shed mEPCR impairs 
the integrity of the endothelium and places the net 
balance of this protective protein in biological 
‘arrears’, a decrease in mEPCR expression was the 
predicted result in patients with progressive renal 
injury. However, it was found that mEPCR is 
highly expressed in the cortical peritubular 
capillaries of kidneys from patients with active LN9. 
Such unexpected behavior was explained by 2 
hypotheses: The first one stated that the increase in 
mEPCR expression represent a physiological 
defense mechanism done by the endothelium, while 
the other hypothesis stated that the circulating 
immune complex deposited on the endothelium 
activates the classical complement pathway which 
in turn binds to protein S impairing its ability to 
generate active protein C and accordingly up 
regulating the receptor6. 
Moreover, mEPCR marker expression failed to 
show a significant difference among patients with 
proliferative and those with non-proliferative LN. 
However, we found that the marker expression was 
still more in the proliferative group as compared to 
those patients within the non-proliferative group. 
This goes in accordance with Mendez and 
colleagues (2013) who did not find any association 
between mEPCR expression and ISN/RPS 
classification when they examined the renal 
biopsies of 34 adult patients with LN25.  Same was 
found by Shabaan et al, 201826. 
On the contrary, Izmirly and colleagues (2012) 
examined non-lesional non-sun exposed areas of 
skin of 27 SLE patients with LN and 5 healthy 
controls. Their study showed that the median % of 
mEPCR positive staining in the dermal blood 
vessels was significantly higher in patients than 
controls (94% versus 59%; P=0.046). There was a 
higher median level of mEPCR expression in 
patients with class III and IV and with biopsies with 
high immune complex deposition versus those of 
class V (96% versus 60%; P=0.029). This median 
% increased in patients with active nephritis (96% 
versus 59%) in comparison to those with inactive 
LN27. 
This wide spread up-regulation in inflamed and 
non-inflamed tissues was explained by the role of 
mEPCR in both endothelial activation and repair. 
This was confirmed by Kurosawa and colleagues 
(1998) who found a significant elevation of the 
soluble form of EPCR in comparison to controls 
and it was also associated with exclusive expression 
of mEPCR on large blood vessels28. 
To find a relation between the degree of marker 
expression and disease activity we compared the 
different laboratory markers at time of renal biopsy 
to the degree of mEPCR expression (lymphocytic 
count, serum creatinine and 24 hours urinary 
protein) and BILAG score done at time of renal 
biopsy. The results showed a statistically significant 
elevated 24 hours urinary protein in 
moderate/severe mEPCR expression compared to 
mild/moderate (P=0.049). This could reflect the 
damage occurring in the vascular integrity because 
of the coagulation defect and the subsequent protein 
loss in urine. This goes in accordance with Izmirly 
and colleagues (2008) as they found that there was 
an increase in marker expression with active 
disease29. The contrary was stated by Mendez and 
colleagues (2013) that could not find any 
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association with mEPCR expression and serum 
creatinine, abnormal GFR and proteinuria25. 
In a trial to explore the prognostic effect of 
mEPCR we compared the degree of mEPCR 
expression to the cumulative doses of different 
immunosuppressive therapy (Steroid, Cyclo-
phosphamide), but we could not find any significant 
difference (P= 0.45, 0.6 respectively). This could be 
attributed to small sample size and uneven 
immunosuppressive intake in patients with SLE that 
could be related to other organ affection. 
The elevated expression of the marker mEPCR 
represents an attempt to preserve an antithrombotic 
state of the microvasculature to generate free active 
protein C to protect the endothelial integrity. 
Accordingly, we compared the degree of its 
expression to activity and chronicity indices, which 
showed that there was an inverse significant 
correlation with chronicity index and not with 
activity index (P= 0.01, 0.69 respectively). This 
supports the hypothesis that mEPCR is an important 
anti-injury molecule in the cascade(s) leading to 
renal damage in SLE9. However, Mendez and 
colleagues (2013) did not find any statistical 
significance between it and both activity and 
chronicity indices25. The same was found by 
Izmirly and colleagues (2009) who stated a non-
significant correlation for activity and chronicity 
indices6. 
In spite that most of the patients who got 
improved had nil/mild marker expression, no 
significant difference was reported between renal 
expression of mEPCR and renal outcome using the 
renal BILAG. 
Mendez and colleagues (2013) found that 75% 
of patients with peritubular staining > 25% did not 
respond to therapy, while 100% of patients with 
staining <25% attained good response25. The same 
was confirmed by Izmirly and colleagues (2009) 
who stated that 84.6% of patients with a score of >2 
did not respond to treatment versus 28.6% in those 
with a score of < 2 (P=0.0018)6. In addition, Izmirly 
and colleagues (2012) stated that the median of 
mEPCR was significantly higher in patients with a 
renal prognostic score >3 than in those with a score 
<3 (P=0.036)27. 
For further proof of its bad prognostic effect in 
renal injury other than LN, Lattenist and colleagues 
(2013) conducted a study on 81 patients with renal 
transplants and assessed acute rejection of kidney 
allografts. They divided those with allograft into T-
cell-mediated rejection (26 patients) and antibody-
mediated rejection (22 patients) and 33 patients 
without rejection. Renal EPCR expression was 
higher in patients with rejection than in control 
patients. Antibody mediated rejection patients had 
more EPCR expression on glomeruli and in 
peritubular capillaries which was explained to be 
protective behavior from the graft24. 
In conclusion , renal expression of mEPCR bore 
a statistically significant difference in relation to 
different LN classes showing more expression in 
the more aggressive classes; a finding which might 
suggest a contribution of the endothelium of the 
renal parenchyma to the pathophysiology of more 
progressive LN. Hence the tissue marker might 
emerge as a potential new therapeutic target in the 
search for more selective treatment for SLE that 
could replace the wide range of immunosuppressive 
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